Hologic (HOLX) Expected to Announce Earnings on Monday

Hologic (NASDAQ:HOLX) is projected to release its Q4 2025 results after the market closes on Monday, November 3rd. Analysts expect Hologic to post earnings of $1.10 per share and revenue of $1.0337 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company earned $1.06 EPS. The firm’s revenue was up 1.2% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Trading Down 0.0%

NASDAQ:HOLX opened at $73.91 on Friday. The company has a market capitalization of $16.44 billion, a P/E ratio of 30.67, a P/E/G ratio of 2.54 and a beta of 0.63. The stock’s 50 day moving average price is $68.26 and its 200 day moving average price is $64.53. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic has a 52 week low of $51.90 and a 52 week high of $84.39.

Insider Activity at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Institutional Trading of Hologic

Several institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. bought a new stake in shares of Hologic during the second quarter valued at approximately $48,283,000. Holocene Advisors LP acquired a new stake in Hologic during the second quarter worth $24,438,000. Raymond James Financial Inc. increased its holdings in Hologic by 52.9% in the 2nd quarter. Raymond James Financial Inc. now owns 567,695 shares of the medical equipment provider’s stock valued at $36,991,000 after buying an additional 196,507 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Hologic by 820.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 86,048 shares of the medical equipment provider’s stock valued at $5,607,000 after buying an additional 76,700 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Hologic by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after acquiring an additional 66,453 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent research reports. Argus upped their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price target on shares of Hologic in a research note on Wednesday, October 22nd. Leerink Partners increased their price objective on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. BTIG Research restated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, Hologic has a consensus rating of “Hold” and an average target price of $79.23.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.